Physician profile
Kimberly Basham
NPI 1790154169
$1,666.62
in general payments reported to CMS, 2019-2025
11 companies · $727 in 2025
The $727 reported for 2025 was more than what 80% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $362 · 2023: $123 · 2024: $455 · 2025: $727.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,304.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $246.72 | 2021-2023 | Farxiga |
| Lilly USA, LLC | $244.89 | 2025 | Zepbound |
| Amgen INC. | $213.28 | 2024-2025 | Repatha, Evenity |
| Dexcom, INC. | $130.81 | 2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161) |
| Ascensia Diabetes Care US INC. | $127.53 | 2024 | |
| Esperion Therapeutics, INC. | $125.00 | 2021 | |
| Glaxosmithkline, LLC. | $123.00 | 2025 | Benlysta |
| Boston Scientific Corporation | $122.98 | 2024 | Watchman Flx |
| Radius Health, INC. | $115.00 | 2024 | Tymlos |
| Sanofi-Aventis U.S. LLC | $112.64 | 2021 | |
| Averitas Pharma INC. | $104.77 | 2025 | Qutenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Basham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.